scholarly journals Effects of continuous subcutaneous apomorphine infusion in Parkinson's disease without cognitive impairment on motor, cognitive, psychiatric symptoms and quality of life

2018 ◽  
Vol 395 ◽  
pp. 113-118 ◽  
Author(s):  
Jean-François Houvenaghel ◽  
Sophie Drapier ◽  
Joan Duprez ◽  
Gabriel Hadrien Robert ◽  
Audrey Riou ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Psychiatric Symptoms ◽  
Subcutaneous Apomorphine

scholarly journals Impact of Depression and Anxiety on Dimensions of Health-Related Quality of Life in Subjects with Parkinson’s Disease Enrolled in an Association of Patients

2021 ◽  
Vol 11 (6) ◽  
pp. 771
Author(s):  
Fany Chuquilín-Arista ◽  
Tania Álvarez-Avellón ◽  
Manuel Menéndez-González
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Psychiatric Symptoms ◽  
Well Being ◽  
Depression And Anxiety ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

Parkinson’s disease (PD) is a complex disorder characterized by a wide spectrum of symptoms. Depression and anxiety are common manifestations in PD and may be determinants of health-related quality of life (HRQoL). The objective of this study is to determine the association of depression and anxiety with the dimensions of HRQoL in subjects with PD enrolled in an association of patients. Ninety-five community-based patients with PD diagnosis at different disease stages were studied. HRQoL was assessed using the Parkinson’s Disease Questionnaire (PDQ-39); depression and anxiety were assessed using the Beck Depression Inventory (BDI-II) and the State-Trait Anxiety Inventory (STAI), respectively. Our results showed that depression and anxiety were negatively associated with HRQoL measured by PDSI. Higher motor dysfunction measured by Hoehn and Yahr (H&Y) staging was also associated with worse HRQoL. Depression was the most influential variable in the model. All PDQ-39 dimensions except social support and bodily discomfort were associated with depression. Anxiety was associated with the emotional well-being and bodily discomfort dimensions. These results suggest that physicians should pay attention to the presence of psychiatric symptoms and treat them appropriately.

Effects of Simulated Horseback Riding on Balance, Postural Sway, and Quality of Life in Older Adults With Parkinson’s Disease

2019 ◽  
Vol 36 (4) ◽  
pp. 413-430 ◽  
Author(s):  
Leah S. Goudy ◽  
Brandon Rhett Rigby ◽  
Lisa Silliman-French ◽  
Kevin A. Becker
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Postural Sway ◽  
Berg Balance Scale ◽  
Horseback Riding ◽  
Scale Scores

The purpose of this study was to determine changes in balance, postural sway, and quality of life after 6 wk of simulated horseback riding in adults diagnosed with Parkinson’s disease. Eight older adults completed two 60-min riding sessions weekly for 6 wk. Variables of balance, postural sway, and quality of life were measured 6 wks before and within 1 wk before and after the intervention. Berg Balance Scale scores decreased from baseline to preintervention (48.36 ± 5.97 vs. 45.86 ± 6.42,p = .050) and increased from preintervention to postintervention (45.86 ± 6.42 vs. 50.00 ± 4.38,p = .002). Cognitive impairment, a dimension of quality of life, improved from baseline to postintervention (37.5 ± 20.5 vs. 21.5 ± 14.4,p = .007). Six weeks of simulated horseback riding may improve balance and cognitive impairment in older adults with Parkinson’s disease.

Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease

2010 ◽  
Vol 258 (3) ◽  
pp. 494-499 ◽  
Author(s):  
Juan Carlos Gómez-Esteban ◽  
Beatriz Tijero ◽  
Johanne Somme ◽  
Roberto Ciordia ◽  
Koldo Berganzo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Sleep Disorders ◽  
Psychiatric Symptoms

scholarly journals Quality of Life and Mild Cognitive Impairment in Early Parkinson’s Disease: Does Subtype Matter?

2015 ◽  
Vol 4 (3) ◽  
pp. 331-336 ◽  
Author(s):  
Rachael A. Lawson ◽  
Alison J. Yarnall ◽  
Gordon W. Duncan ◽  
Tien K. Khoo ◽  
David P. Breen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Parkinson’S Disease

Deep Brain Stimulation in Patients with Parkinson's Disease: Effect on Psychiatric Symptoms and Quality of Life

2017 ◽  
Vol 79 (02) ◽  
pp. 130-138
Author(s):  
Elisa Seijo Zazo ◽  
Fernando Fernandez ◽  
Elena Liebana ◽  
Antonio Ayala ◽  
Beatriz Aragoneses ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Deep Brain Stimulation ◽  
Psychiatric Symptoms ◽  
Medication Use ◽  
Sf 36 ◽  
Deep Brain

Background and Study Aims To determine the effect on psychiatric symptoms and quality of life in 30 patients with Parkinson's disease (PD) treated with deep brain stimulation (DBS) of both subthalamic nuclei (STN) after 1 year of follow-up. Material and Method We conducted a prospective 1-year follow-up study with a baseline assessment before and 6 and 12 months after surgery. The following were used as assessment instruments: the Bech-Rafaelsen Melancholia Scale (MES), the Bech-Rafaelsen Mania Scale (MAS), the Beck Scale for Suicidal Ideation (SSI), the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Oviedo Sleep Questionnaire (OSQ), the 36-Item Short Form Health Survey (SF-36), the Unified Parkinson's Disease Rating Scale (UPDRS), the dose of levodopa, and the active contact stereotactic coordinates. Results We recorded a clinical improvement between baseline with medication use (ON medication) and the results obtained at 6 and 12 months with medication use and stimulation (ON stimulation, ON medication) in MES and OSQ (p < 0.0001) and in SF-36 (p < 0.005). No changes were observed in MAS and SSI. There was a clinical improvement between baseline with ON medication and the results obtained at 12 months with ON stimulation, ON medication in Y-BOCS (p < 0.04). Also, there was a 53.3% reduction in levodopa at 6 months and a 54.7% reduction at 12 months after surgery (p < 0.0001). There was an improvement between baseline with OFF medication and the results obtained at 6 and 12 months OFF medication, ON stimulation (p < 0.0001) in UPDRS-III. There were no statistically significant differences between the initial and final active contact coordinates, or between stimulation parameters. Conclusions DBS of the STN in patients with PD is associated with an improvement in psychiatric (affective and sleep-wake cycle) symptoms, clinical motor symptoms, and quality of life at 1 year after surgery.

scholarly journals Severity of mild cognitive impairment in early Parkinson's disease contributes to poorer quality of life

2014 ◽  
Vol 20 (10) ◽  
pp. 1071-1075 ◽  
Author(s):  
Rachael A. Lawson ◽  
Alison J. Yarnall ◽  
Gordon W. Duncan ◽  
Tien K. Khoo ◽  
David P. Breen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Early Parkinson’S Disease

Cognitive Interventions in Parkinson’s Disease

2017 ◽  
Author(s):  
Sarah Banks
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Cognitive Impairments ◽  
Cognitive Domain ◽  
Future Directions ◽  
Cognitive Interventions ◽  
Nonmotor Symptom

People with Parkinson’s disease frequently demonstrate cognitive impairments, ranging from isolated cognitive impairments to frank dementia. Cognitive dysfunction in Parkinson’s disease has a clear impact on quality of life and independence; hence, there is a need to develop treatments that will reliably improve this important nonmotor symptom. Executive functions are the most frequently impacted cognitive domain, and they have been shown in other populations to be amenable to cognitive interventions. This chapter reviews the literature on cognitive interventions in Parkinson’s disease, and it places the literature into the context of cognitive impairment in Parkinson’s disease. It also reviews studies of cognitive interventions for other conditions. Current gaps in our understanding are highlighted, and proposals for future directions of research in this field are provided.

Sign in / Sign up

Export Citation Format

Share Document